Abstract
In response to rapidly increasing MRI utilization for prostate cancer (PCa) diagnosis and management, concerns about quality of prostate MRI scans and interpretation, lack of stakeholder consensus, and inconsistent guidelines and insurance coverage, the ACR convened the Stakeholder Prostate Summit on September 6, 2019. The aims were to (1) identify obstacles to adoption, (2) explore the role of nuclear medicine in prostate cancer (PCa) diagnosis, (3) assess ACR PCa initiatives, (4) build consensus about the role of MRI in PCa diagnosis in biopsy-naïve men and those managed with active surveillance, and (5) make recommendations to the radiology community and ACR leadership to support efforts to improve quality and access to prostate MRI.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
